Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
IDEAYA Biosciences
Molecular Partners AG
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Technische Universität Dresden
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
Tanabe Pharma America, Inc.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
AbbVie
M.D. Anderson Cancer Center
Phanes Therapeutics
Vyriad, Inc.
Travera Inc
Fox Chase Cancer Center
Turning Point Therapeutics, Inc.
Hoffmann-La Roche
Hansoh BioMedical R&D Company
National Institutes of Health Clinical Center (CC)
Hoffmann-La Roche
National Cancer Institute (NCI)
Travera Inc
Fudan University
National Cancer Institute (NCI)
Xencor, Inc.
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
The University of Texas Health Science Center, Houston